Miltenyi Biotec is deeply committed to empowering research and advancing therapy. For us this means that we are part of the scientific community, contributing to more than 100 national and international grant projects since the foundation of our company.
Here we present current examples of our cutting-edge collaborations funded by EU and national sources.
CD20 CAR transduced T cells for individualized melanoma therapy
Antigen reactive T cells for diagnosis and therapy of fungus-associated diseases in high-risk patients
Induced pluripotent stem cells for cellular therapy of cardiac diseases
Generation of GMP-compliant induced pluripotent stem cells from universal donors.
Sub-project: Development of prototypes and material for GMP-compliant production of iPS cells
Generation of transplantable hiPSC-derived retinal cells for treatment of retinal degeneration
Advanced confocal light sheet microscopy for clinical high-throughput analysis of immune cell infiltration of tumor samples.
Sub-project: Development, verification and adaptation of specific probes for light sheet microscopy
Professional cross-priming for ovary and prostate cancer
Developing Genetic medicines for Severe Combined Immunodeficiency
Chimeric Antigen Receptors for Advanced Therapies
Silicon Nitride Photonic Integrated Circuit Pilot line for Life Science Applications in the Visible Range
Transfer of multivirus-specific T-cells following transplantation
Manufacturing of Tumour-Reactive Natural Killer cells
Interdisciplinary training network for advancing Organ-on-a-chip technology in Europe
Quantitative detection of bacterial endotoxin by novel nanotechnological approaches
Peptide-based immunization strategies for Colon and Pancreas carcinomas
Analysis of biomarkers for the detection of apheresis responders and glucocorticosteroid responders in multiple sclerosis patients with acute disease relapse
Development of an immunotherapy for acute myeloid leukaemias (AMLs) using allogeneic natural killer (NK) cells with CD33 CARs
Development of new predictive markers for response to immune checkpoint inhibitors of solid tumors